Obermatt

Shionogi

TYO:4507 · JP3347200002
PharmaceuticalsX-Large

360

70
EV / EBIT78
Price / Owner Earnings84
Owner Earnings Yield94
Dividend Yield95
Price/Sales44
EV / Gross Profit58
Price/Book65
Return on Capital19
Cash Return on Capital64
Return on Equity53
EBIT Margin74
Gross Profitability10
Cash Conversion25
Accruals6
Owner Earnings Margin96
Sales growth91
Profit Growth59
Long-Term EPS Growth42
Owner Earnings Growth40
Reinvestment100
Price momentum91
Debt load44
Refinancing38
Debt Payback100
Liquidity75
Analyst ratings8
Opinion Changes50
Price Target Upside72
Market mood79
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Shionogi generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryJapan
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeTSE
Founded1919
Employees281
ISINJP3347200002
Last UpdateApr 2, 2026
Themes
Pain ManagementHealth DiagnosticsVaccinesDiabetesCardiovascularInfectious DiseasesAllergyOncologyBiotechnologyMedicalPharmaceutical

Description

Shionogi & Co., Ltd. engages in the manufacture and sale of pharmaceutical products, diagnostics, and other related products. The Company specializes in three product areas related to cardiovascular and metabolic diseases; infectious diseases and imm…

Analysis

Bargain bin

Shionogi & Co., Ltd. falls in the bargain bin: the price is low relative to peers, but the business metrics give reason to pause.

The price is attractive. You pay 10.1× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -3% yearly growth; analysts expect 10%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is adequate. The company scores 14/20 on our value-creation score: strong value creator.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
94
2023202420252026

All-time high

99

Jan 2023

All-time low

53

Jan 2024

Average rank

82

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
44
22
19
22
Price/Earnings
57
83
79
69
Price/Book
65
52
53
52
Dividend Yield
95
70
58
62
Value (overall)
88
58
50
49

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Shionogi with its peers
Hanmi Pharmaceutical
KSC:128940
76
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Kukje Pharma
KSC:002720
43
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Dongwha Pharm
KSC:000020
44
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Medical Developments International
ASX:MVP
79
CountryAustralia
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Celltrion
KSC:068270
79
CountrySouth Korea
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
PharmGen Science
KSC:004720
74
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →